Longer intervals between SARS-CoV-2 infection and mRNA-1273 doses improve the neutralization of different variants of concern

The humoral immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern elicited by vaccination was evaluated in COVID-19 recovered individuals (Rec) separated 1-3 months (Rec2m) or 4-12 months (Rec9m) postinfection and compared to the response in naïve p...

Descripción completa

Detalles Bibliográficos
Autores: García-Pérez, Javier, Bermejo, Mercedes, Ramírez-García, Almudena, de la Torre-Tarazona, Humberto Erick, Cascajero Díaz, Almudena, Castillo de la Osa, María, Jiménez Santana, Paloma, Aparicio Gómez, Marta, Calonge, Esther, Sancho-López, Aránzazu, Payares-Herrera, Concepción, Layunta Acero, Rocio, Vicente-Izquierdo, Laura, Avendaño-Solá, Cristina, Alcamí, José, Perez-Olmeda, Mayte, Díez-Fuertes, Francisco
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/16083
Acceso en línea:http://hdl.handle.net/20.500.12105/16083
Access Level:acceso abierto
Palabra clave:COVID-19
Humans
2019-nCoV Vaccine mRNA-1273
SARS-CoV-2
mRNA Vaccines
Biological Assay
Vaccination
Antibodies, Neutralizing
Antibodies, Viral
Spike Glycoprotein, Coronavirus
Descripción
Sumario:The humoral immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern elicited by vaccination was evaluated in COVID-19 recovered individuals (Rec) separated 1-3 months (Rec2m) or 4-12 months (Rec9m) postinfection and compared to the response in naïve participants. Antibody-mediated immune responses were assessed in 66 participants by three commercial immunoassays and a SARS-CoV-2 lentiviral-based pseudovirus neutralization assay. Immunoglobulin (Ig) levels against SARS-CoV-2 spike were lower in naïve participants after two doses than in Rec after a single dose (p < 0.05). After two doses in Rec, levels of total Ig to receptor-binding domain were significantly increased in Rec9m compared to Rec2m (p < 0.001). The neutralizing potency observed in Rec9m was consistently higher than in Rec2m against variants of concern (VOCs) Alpha, Beta, Delta, and BA.1 sublineage of Omicron with 2.2-2.8-fold increases. Increasing the interval between SARS-CoV-2 infection and the vaccination with messenger RNA-based vaccines to more than 3 months generates a more efficient heterologous humoral immune response against VOCs by allowing enough time to mount a strong recall memory B cell response.

Similares en LA Referencia